May 4, 2025

Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial.

Holzmann C, Karg J, Reiger M et al. Allergy. 2025 Apr 17. doi: 10.1111/all.16558. 

ABSTRACT

Background

Symptom monitoring can improve adherence to daily medication. However, controlled clinical trials on multi-modular allergy apps and their various functions have been difficult to implement.

Graphical Abstract
The objective of this study was to assess the clinical benefit of an allergy app with varying numbers of functions in reducing symptoms and improving quality of (QoL) life in grass pollen allergic individuals. The secondary objective was to develop a symptom forecast based on patient-derived and environmental data.

Methods

We performed a stratified, controlled intervention study (May–August 2023) with grass pollen allergic participants (N = 167) in Augsburg, Germany.

Dermatologic presentations of hyper IgE syndrome in pediatric patients

Mahjoubi, M., Rashedi, R., Samieefar, N. et al. Allergy Asthma Clin Immunol 21, 20 (2025). https://doi.org/10.1186/s13223-025-00963-6


Abstract

Background

Generalized erythematous and excoriated papules
suggesting an eczematous dermatitis in a
10-year-old boy with HIES
Hyper-IgE Syndrome, also known as Job’s syndrome, is a rare primary immunodeficiency disorder characterized by recurrent infections and elevated levels of immunoglobulin E. While respiratory and systemic manifestations have been more emphasized, dermatological manifestations in Hyper-IgE Syndrome also play a significant role in disease presentation.

Methods

This narrative review explores the dermatologic presentations of Hyper-IgE Syndrome in pediatric populations

May 3, 2025

First-in-Class Intranasal Epinephrine Spray for Anaphylaxis: Dose Finding Clinical Study

Lapidot, Tair et al. Journal of Allergy and Clinical Immunology: Global, Volume 0, Issue 0, 100487

Abstract

Background

Anaphylaxis is a life-threatening clinical presentation of acute systemic allergic reactions. Timely administration of epinephrine, usually by intramuscular autoinjector, is a robust life-saving treatment. Despite the critical necessity, there are multiple deterrants to patients’ proper use of epinephrine autoinjectors. FMXIN002 is a novel nasal dry powder formulation of epinephrine in a single-use device, offering first-in-class alternative treatment.

Objective

To measure epinephrine pharmacokinetics, pharmacodynamics and safety following a single administration of FMXIN002 at doses of 3.6 and 4.0 mg epinephrine versus IM autoinjector 0.3 mg, in healthy adults.

Methods

An open-label, single-dose, three-treatment, crossover, randomized, comparative bioavailability study with 12 healthy adults, female and male. FMXIN002 stability was also tested.

Results

FMXIN002 4.0 mg was absorbed faster and higher by most of the subjects, compared to IM autoinjector. 91% of subjects achieved the clinical threshold of 100 pg/mL plasma epinephrine at 6 minutes after administration of FMXIN002 4.0mg compared to 55% of subjects treated with IM autoinjector.

May 2, 2025

Association of ulcerative colitis with atopic dermatitis: identification of shared and unique mechanisms by construction and computational analysis of disease maps

Oxana Lopata, Marcio Luis Acencio, Xinhui Wang, Ahmed Abdelmonem Hemedan, Michael J. Chao, Scott A Jelinsky, Florian Tran, Philip Rosenstiel, Andrew Y.F. Li Yim, Reinhard Schneider, Venkata Satagopam, Marek Ostaszewski bioRxiv 2025.04.23.650149; doi: https://doi.org/10.1101/2025.04.23.650149

ABSTRACT

Background and Aims Ulcerative colitis (UC) and atopic dermatitis (AD) are immune-mediated inflammatory diseases with limited treatment options. They are known to be related which may explain higher risk of development of UC in patients with AD. The goal of this work is to review and analyse molecular mechanisms of UC in comparison to AD towards insights into UC complexity, potential comorbidities and novel therapies.

Methods We developed graphical computational models of UC and AD molecular mechanisms (disease maps) by integrating information from over 800 manually curated articles. The maps are available online at https://imi-immuniverse.elixir-luxembourg.org. Disease-specific risk variants and gene expression profiles are visualised to identify signatures specific to UC, and shared with AD.

May 1, 2025

National best practice guidelines for anaphylaxis prevention and management in Australian schools

Netting, Merryn J. et al. Journal of Allergy and Clinical Immunology: Global, Volume 4, Issue 2, 100413

Abstract

Background

Anaphylaxis prevention and management in the school setting is an important health and safety issue as the rates of food allergy in children continue to increase.

Objective

We describe the development and review of the Australian National Allergy Council best practice guidelines for anaphylaxis prevention and management in schools.

Methods

Developed in consultation with key stakeholders in health and education settings, the best practice guidelines incorporate 7 key recommendations for anaphylaxis prevention and management: an allergy aware approach; anaphylaxis management policy and plans; allergy documentation; emergency response; staff training; community and student education; and postincident management and incident reporting.

April 30, 2025

Reduction in Artemisia Pollen-Specific IgE Levels During House Dust Mite Allergen Immunotherapy in Polysensitized Allergic Rhinitis Patients: A Three-Year Retrospective Study in Northern, China

Sun X, Li X, Gao T, Liu P, Liu N, Jin P, Zhi L. J Asthma Allergy. 2025;18:665-673 https://doi.org/10.2147/JAA.S525620

Abstract

Background:  Allergen immunotherapy (AIT) is a well-established treatment for allergic diseases, particularly in patients with allergic rhinitis and asthma. In regions where patients are polysensitized, AIT can have broader immunomodulatory effects. This study investigates the impact of house dust mite AIT on IgE responses to both dust mites and non-target allergens, specifically Artemisia pollen, in polysensitized allergic rhinitis patients.

Methods:  This retrospective study included polysensitized patients aged 18 or older with a diagnosis of allergic rhinitis or rhinitis with asthma and positive IgE for both house dust mites and Artemisia pollen. Patients who completed at least three years of AIT for house dust mites were included. IgE levels for Dermatophagoides pteronyssinus (Der p), Dermatophagoides farinae (Der f), and Artemisia pollen were measured at baseline and after 1, 2, and 3 years of treatment.

April 28, 2025

Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical Therapies

Gooderham, M.J., Hong, H.Ch., Lynde, C. et al.  Dermatol Ther (Heidelb) (2025). https://doi.org/10.1007/s13555-025-01386-2

Abstract

Introduction

Atopic dermatitis (AD) is a highly prevalent disease in Canada with significant patient burden. Treatment guidance for topical therapy (the mainstay of AD management), with particular consideration of emerging treatments, may further improve patient care. Here, we aim to provide healthcare professionals with AD treatment recommendations from the perspective of 10 Canadian dermatologists with expertise in managing AD.

Methods

The panel of dermatologists conducted a systematic literature review and leveraged their clinical experience to develop generally accepted principles, consensus statements, and a treatment algorithm using an iterative consensus process.

Results

The panel collectively developed six generally accepted principles, 10 consensus statements, and a treatment algorithm. The guidance notes that assessment of disease severity should encompass both physician-rated measures and patient-reported outcomes. Disease education, lifestyle-based strategies (e.g., trigger avoidance), and supportive measures (e.g., moisturizers) can help reduce signs and symptoms of AD.

Oral Immunotherapy in Peanut-Allergic Adults Using Real-World Materials

Hunter H, Ue KL, Cornelius V, Yung CC, Thomas I, Tsilochristou O, Layhadi J, Siew LQC, Venter C, Shamji MH, Till SJ. Allergy. 2025 Apr 23. doi: 10.1111/all.16493. 

ABSTRACT

Background

Peanut oral immunotherapy (OIT) has shown effectiveness in achieving desensitization of children; however, evidence in adults is lacking.

Methods

Graphical Abstract

This phase II trial evaluated peanut OIT in peanut-allergic adults using real-world peanut products. A Simon's minimax two-stage design, incorporating a stop:go for futility, was employed.